Literature DB >> 33106265

KPC-53, a KPC-3 Variant of Clinical Origin Associated with Reduced Susceptibility to Ceftazidime-Avibactam.

Vincenzo Di Pilato1, Noemi Aiezza2, Valentina Viaggi3, Alberto Antonelli2,4, Luigi Principe3, Tommaso Giani2,4, Francesco Luzzaro3, Gian Maria Rossolini5,4.   

Abstract

This study reports on the characterization of a Klebsiella pneumoniae clinical isolate showing high-level resistance to ceftazidime-avibactam associated with the production of KPC-53, a KPC-3 variant exhibiting a Leu167Glu168 duplication in the Ω-loop and a loss of carbapenemase activity. Whole-genome sequencing (WGS) revealed the presence of two copies of bla KPC-53, located on a pKpQIL-like plasmid and on a plasmid prophage of the Siphoviridae family, respectively. The present findings provide new insights into the mechanisms of resistance to ceftazidime-avibactam.
Copyright © 2020 American Society for Microbiology.

Entities:  

Keywords:  CZA resistance; carbapenem-resistant Enterobacterales; mutant KPC carbapenemase; phagemid

Year:  2020        PMID： 33106265      PMCID： PMC7927837          DOI： 10.1128/AAC.01429-20

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  18 in total

1.  MgrB inactivation is a common mechanism of colistin resistance in KPC-producing Klebsiella pneumoniae of clinical origin.

Authors:  Antonio Cannatelli; Tommaso Giani; Marco Maria D'Andrea; Vincenzo Di Pilato; Fabio Arena; Viola Conte; Kyriaki Tryfinopoulou; Alkiviadis Vatopoulos; Gian Maria Rossolini
Journal:  Antimicrob Agents Chemother       Date:  2014-07-14       Impact factor: 5.191

2.  KPC-31 expressed in a ceftazidime/avibactam-resistant Klebsiella pneumoniae is associated with relevant detection issues.

Authors:  Alberto Antonelli; Tommaso Giani; Vincenzo Di Pilato; Eleonora Riccobono; Gabriele Perriello; Antonella Mencacci; Gian Maria Rossolini
Journal:  J Antimicrob Chemother       Date:  2019-08-01       Impact factor: 5.790

Review 3.  Phenotypic Detection of Carbapenemase-Producing Organisms from Clinical Isolates.

Authors:  Pranita D Tamma; Patricia J Simner
Journal:  J Clin Microbiol       Date:  2018-10-25       Impact factor: 5.948

4.  Klebsiella pneumoniae carbapenemase (KPC) producer resistant to ceftazidime-avibactam due to a deletion in the blaKPC3 gene.

Authors:  E Antinori; I Unali; A Bertoncelli; A Mazzariol
Journal:  Clin Microbiol Infect       Date:  2020-02-12       Impact factor: 8.067

5.  Ceftazidime-Avibactam Resistance Associated with Increased bla KPC-3 Gene Copy Number Mediated by pKpQIL Plasmid Derivatives in Sequence Type 258 Klebsiella pneumoniae.

Authors:  Marco Coppi; Vincenzo Di Pilato; Francesco Monaco; Tommaso Giani; Pier Giulio Conaldi; Gian Maria Rossolini
Journal:  Antimicrob Agents Chemother       Date:  2020-03-24       Impact factor: 5.191

6.  Patient-to-Patient Transmission of Klebsiella pneumoniae Carbapenemase Variants with Reduced Ceftazidime-Avibactam Susceptibility.

Authors:  L Silvia Munoz-Price; Allison E Reeme; Blake W Buchan; Roberta T Mettus; Mustapha M Mustapha; Daria Van Tyne; Ryan K Shields; Yohei Doi
Journal:  Antimicrob Agents Chemother       Date:  2019-09-23       Impact factor: 5.191

Review 7.  Resistance to ceftazidime-avibactam and underlying mechanisms.

Authors:  Yuhang Wang; Jin Wang; Rui Wang; Yun Cai
Journal:  J Glob Antimicrob Resist       Date:  2019-12-19       Impact factor: 4.035

8.  OmpK36-mediated Carbapenem resistance attenuates ST258 Klebsiella pneumoniae in vivo.

Authors:  Joshua L C Wong; Maria Romano; Louise E Kerry; Hok-Sau Kwong; Wen-Wen Low; Stephen J Brett; Abigail Clements; Konstantinos Beis; Gad Frankel
Journal:  Nat Commun       Date:  2019-09-02       Impact factor: 14.919

9.  Genomic analysis of 40 prophages located in the genomes of 16 carbapenemase-producing clinical strains of Klebsiella pneumoniae.

Authors:  Ines Bleriot; Rocío Trastoy; Lucia Blasco; Felipe Fernández-Cuenca; Antón Ambroa; Laura Fernández-García; Olga Pacios; Elena Perez-Nadales; Julian Torre-Cisneros; Jesús Oteo-Iglesias; Ferran Navarro; Elisenda Miró; Alvaro Pascual; German Bou; Luis Martínez-Martínez; Maria Tomas
Journal:  Microb Genom       Date:  2020-04-29

Review 10.  Bacteriophages of Klebsiella spp., their diversity and potential therapeutic uses.

Authors:  Warren P Herridge; Preetha Shibu; Jessica O'Shea; Thomas C Brook; Lesley Hoyles
Journal:  J Med Microbiol       Date:  2020-01-24       Impact factor: 2.472
View more
  8 in total

1.  Co-resistance to ceftazidime-avibactam and cefiderocol in clinical isolates producing KPC variants.

Authors:  Laurent Poirel; Mustafa Sadek; Ayda Kusaksizoglu; Patrice Nordmann
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2022-01-28       Impact factor: 3.267

2.  A Two Amino Acid Duplication, L167E168, in the Ω-Loop Drastically Decreases Carbapenemase Activity of KPC-53, a Natural Class A β-Lactamase.

Authors:  Alessandra Piccirilli; Sabrina Cherubini; Giuseppe Celenza; Gian Maria Rossolini; Fabrizia Brisdelli; Bernardetta Segatore; Luigi Principe; Francesco Luzzaro; Lilia Andriani; Gianfranco Amicosante; Mariagrazia Perilli
Journal:  Antimicrob Agents Chemother       Date:  2022-06-01       Impact factor: 5.938

3.  Increased gene expression and copy number of mutated blaKPC lead to high-level ceftazidime/avibactam resistance in Klebsiella pneumoniae.

Authors:  Lingxiao Sun; Haibo Li; Qi Wang; Yingmei Liu; Bin Cao
Journal:  BMC Microbiol       Date:  2021-08-19       Impact factor: 3.605

Review 4.  Resistance to Ceftazidime/Avibactam, Meropenem/Vaborbactam and Imipenem/Relebactam in Gram-Negative MDR Bacilli: Molecular Mechanisms and Susceptibility Testing.

Authors:  Paolo Gaibani; Tommaso Giani; Federica Bovo; Donatella Lombardo; Stefano Amadesi; Tiziana Lazzarotto; Marco Coppi; Gian Maria Rossolini; Simone Ambretti
Journal:  Antibiotics (Basel)       Date:  2022-05-06

5.  KPC-39-Mediated Resistance to Ceftazidime-Avibactam in a Klebsiella pneumoniae ST307 Clinical Isolate.

Authors:  Agnès B Jousset; Saoussen Oueslati; Cécile Emeraud; Rémy A Bonnin; Laurent Dortet; Bogdan I Iorga; Thierry Naas
Journal:  Antimicrob Agents Chemother       Date:  2021-10-04       Impact factor: 5.191

6.  Successful Treatment of Bloodstream Infection due to a KPC-Producing Klebsiella Pneumoniae Resistant to Imipenem/Relebactam in a Hematological Patient.

Authors:  Paolo Gaibani; Linda Bussini; Stefano Amadesi; Michele Bartoletti; Federica Bovo; Tiziana Lazzarotto; Pierluigi Viale; Simone Ambretti
Journal:  Microorganisms       Date:  2022-04-05

7.  Activity of N-Acetylcysteine Alone and in Combination with Colistin against Pseudomonas aeruginosa Biofilms and Transcriptomic Response to N-Acetylcysteine Exposure.

Authors:  Felice Valzano; Selene Rebecca Boncompagni; Maria Micieli; Tiziana Di Maggio; Vincenzo Di Pilato; Lorenzo Colombini; Francesco Santoro; Gianni Pozzi; Gian Maria Rossolini; Lucia Pallecchi
Journal:  Microbiol Spectr       Date:  2022-06-23

8.  Evolutionary Trajectories toward Ceftazidime-Avibactam Resistance in Klebsiella pneumoniae Clinical Isolates.

Authors:  Alessandra Carattoli; Gabriele Arcari; Giulia Bibbolino; Federica Sacco; Dario Tomolillo; Federica Maria Di Lella; Maria Trancassini; Luigi Faino; Mario Venditti; Guido Antonelli; Giammarco Raponi
Journal:  Antimicrob Agents Chemother       Date:  2021-08-02       Impact factor: 5.191
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.